Your session is about to expire
← Back to Search
CTI-1601 for Friedreich's Ataxia
Study Summary
This trial will evaluate if a medicine is safe/well-tolerated, and its effects on Friedreich's ataxia over 28 days.
- Friedreich Ataxia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your heart's electrical activity, as measured by an ECG, is too slow.You take more than 3.0 grams of acetaminophen every day.You need to take amiodarone.You have taken omaveloxolone within the last 30 days before screening.You are taking a medication that needs to be injected under the skin in your belly or thigh.You have a specific genetic mutation related to Friedreich's ataxia.You have a confirmed genetic diagnosis of FRDA with specific GAA repeat expansions.You have taken more than 30.0 mcg/day of biotin (found in some multivitamins or standalone supplements) within 7 days before starting the study drug.Your heart's pumping ability, measured by a screening test called ECHO, is less than 45%.You have taken erythropoietin, etravirine, or gamma interferon in the 90 days before the screening.
- Group 1: CTI-160l
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any fresh volunteers currently being accepted for this research?
"Affirmative. The information hosted on clinicaltrials.gov verifies that this particular medical experiment is actively accepting volunteers, having been posted on September 21st 2022 and recently updated on October 11th 2022. 15 subjects are sought from 1 site for enrolment in the trial."
Has the FDA officially validated CTI-160l?
"Considering the nature of this Phase 2 trial, wherein safety has been demonstrated but efficacy remains unknown, our team at Power have assigned CTI-160 a score of 2 on their scale from 1 to 3."
What is the projected sample size for this clinical research?
"Affirmative, clinicaltrials.gov hosts evidence that this medical survey is presently in the process of recruiting participants. It was opened for enrollment on September 21st 2022 and edited most recently on October 11th 2022. Fifteen patients have to be enrolled from 1 site."
Share this study with friends
Copy Link
Messenger